What the 12-month number counts

STAR-TREC randomised more than 500 patients in the United Kingdom, the Netherlands, Denmark, Belgium and Sweden between standard radical surgery and two organ-preserving routes: five weeks of chemoradiotherapy or five days of short-course radiotherapy, with rectum-preserving surgery added only when it was needed. At 12 months, four in five of the patients treated with chemoradiotherapy still had their rectum, and that route came out ahead of the short course.[1]

The endpoint behind that fraction is the organ itself, counted at a fixed moment. It tells us how many people reached 12 months with a rectum, which is exactly what a permanent stoma takes away, and it leaves open how many of them will still be clear of the tumour later.[1]

The three years that decide it

The investigators say they are following these patients for the next three years to see whether the cancer is more likely to come back when radical surgery is skipped. Until that reads out, the accurate description of the trial is a comparison between two ways of keeping the rectum, one of which did better at 12 months. Whether the approach becomes routine care will turn on those recurrence figures rather than on the 12-month result.[1]

The straightforward reading of why the five-week course pulled ahead is dose and time: more treatment before the response is judged leaves fewer tumours that still need the operation. A second explanation fits the same result. Response-adapted care means a clinician decides whether to operate, this was an open-label trial, and knowing which arm a patient is in gives that judgement room to move.[1]

Who is inside the denominator

Around 4,100 people in England are diagnosed with early-stage rectal cancer each year, and STAR-TREC recruited from the United Kingdom, the Netherlands, Denmark, Belgium and Sweden. Everything the result promises depends on services that can deliver five weeks of chemoradiotherapy, reassess the tumour afterwards and hold an operation in reserve.[1]

The human stake is stated plainly by the trial's own co-chief investigator, Simon Bach, who describes the loss of the rectum and often a permanent stoma as the price patients have been asked to accept for a cure. Keeping four in five people off that trade at 12 months is worth having on its own terms. The figure that settles the question is the one still being gathered.[1]